Immix Biopharma, Inc.
Moat Score — Immix Biopharma, Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Immix holds global exclusive patent rights to its N-GENIUS platform and NXC-201, with expected expiration around 2043 (and a 2045 family for a newer platform), plus multiple FDA/EU regulatory designations (RMAT, Orphan Drug, Breakthrough Therapy) that function as quasi-intangible barriers, though the underlying CAR-T science is in-licensed rather than wholly originated in-house. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a clinical-stage CAR-T developer reliant entirely on third-party contract manufacturers, Immix has no cost advantage over other cell-therapy developers; CAR-T manufacturing economics are an industry-wide challenge rather than a company-specific edge. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | If approved, NXC-201 would likely be the first therapy for relapsed/refractory AL amyloidosis, a serious disease with no current FDA-approved treatment option, which would support meaningful orphan-drug pricing power, though this remains unrealized until regulatory approval and commercial launch actually occur. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Immix's cell-therapy business has no network effect; broader adoption by one treatment center does not increase the product's value to the next patient or physician. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Because NXC-201 is a one-time or limited-course CAR-T therapy rather than a chronic maintenance drug, there is little ongoing switching-cost dynamic once a patient is treated; any moat here is closer to first-mover advantage than true switching costs. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | AL amyloidosis is a genuinely small, orphan-sized patient population (~38,500 U.S. patients in 2026 by the company's own estimate), which may be too small to support multiple competing CAR-T therapies profitably once one is approved, giving a durable incumbency advantage to whichever company gets there first. |